Spinal Cord Diseases  >>  ozanezumab (GSK 1223249)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ozanezumab (GSK 1223249) / GSK
NCT01753076: Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Completed
2
304
Japan, US, Canada, Europe, RoW
Ozanezumab, Placebo
GlaxoSmithKline
Amyotrophic Lateral Sclerosis
01/15
01/15

Download Options